Hypertension and the eye: Changing perspectives

Journal of Human Hypertension

Volumn 16, Issue 10, 2002, Pages 667-675

  Chatterjee, S ^a   Chattopadhya, S ^b   Hope Ross, M ^a   Lip, P L ^a  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Classification; Hypertensive retinopathy; Target organ damage

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LEPTIN;

ARTERIOSCLEROSIS; BRAIN DISEASE; CARDIOVASCULAR RISK; CHORIORETINOPATHY; CLINICAL TRIAL; CRANIAL NERVE PARALYSIS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EYE DISEASE; GENETIC POLYMORPHISM; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPERTENSION RETINOPATHY; ISCHEMIA; KIDNEY FAILURE; MICROALBUMINURIA; MORBIDITY; MORTALITY; NONHUMAN; OPTIC NERVE DISEASE; ORGAN INJURY; PATHOGENESIS; PATHOPHYSIOLOGY; PROGNOSIS; RACE DIFFERENCE; RETINA VEIN OCCLUSION; RETINOPATHY; REVIEW; RISK MANAGEMENT; SALT INTAKE; SMOKING HABIT; STROKE; VASCULAR DISEASE;

EYE DISEASES; HUMANS; HYPERTENSION; PROGNOSIS; RISK FACTORS;

EID: 0036813154     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001472     Document Type: Review

References (89)

1. Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 167: 2413-2446.
2. Hayreh SS. Systemic arterial blood pressure and the eye. Duke-Elder Lecture. Eye 1996; 10: 5-28.
3. Hayreh S, Servais G, Virdi P, Marcus M, Rojas P, Woolson R. Fundus lesions in malignant hypertension: III. Arterial blood pressure, biochemical and fundus changes. Ophthalmology 1986; 93: 45-59.
4. Klein R. Retinopathy in a population-based study. Trans Am Ophth Soc 1992; 90: 561-594.
5. Klein R, Klein B, Moss S. Blood pressure, hypertension and retinopathy in a population. Trans Am Ophth Soc 1993; 91: 207-222.
6. Klein R, Klein B, Moss S, Wang Q. Hypertension and retinopathy, arteriolar narrowing and arteriovenous nicking in a population. Arch Ophthalmol 1994; 112: 92-98.
7. Yu T et al. Retinopathy in older persons without diabetes and its relationship to hypertension. Arch Ophthalmol 1998; 116: 83-89.
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
9. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-719.
10. Sjolie AK et al. The EURODIAB IDDM Complications Study Group. Retinopathy and vision loss in insulin-dependent diabetes in Europe. Ophthalmology 1997; 104: 252-260.
11. Sharp PS et al. Hypertensive retinopathy in Afro-Caribbeans and Europeans: Prevalence and risk factor relationships. Hypertension 1995; 25: 1322-1325.
12. Poulter NR. Independent effects of smoking on risk of hypertension: Small, if present. J Hypertens 2002; 20: 171-172.
13. Tuomilehto J, Elo J, Nissmen A. Smoking among patients with malignant hypertension. BMJ 1982; 1: 1086.
14. Isles C et al. Excess smoking in malignant-phase hypertension. BMJ 1979; 1: 579-581.
15. Bloxham CA, Beevers DG, Walker JM. Malignant hypertension and cigarette smoking. BMJ 1979; 1: 581-583.
16. Ahmed ME, Walker JM, Beevers DG, Beevers M. Lack of difference between malignant and accelerated hypertension. BMJ (Clin Res Ed) 1986; 25: 292(6515); 235-237.
17. Nakano Y et al. DD genotype of the angiotensin 1-converting enzyme gene is a risk factor for early onset of essential hypertension in Japanese patients. J Lab Clin Med 1998; 131: 502-506.
18. Pontremoli R et al. The deletion polymorphism of the angiotensin 1-converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 1996; 7: 2550-2558.
19. Yilmaz H, Isbir T, Agachan B, Aydin M. Is epsilon4 allele of apolipoprotein E associated with more severe end-organ damage in essential hypertension? Cell Biochem Funct 2001; 19: 191-195.
20. Ravera M et al. 10-methylenetetrahydrofolate reductase polymorphism and early organ damage in primary hypertension. Am J Hypertens 2001; 14: 371-378.
21. Hattenbach L-O. et al. Absence of hypertensive retinopathy in a Turkish kindred with autosomal dominant hypertension and brachydactyly. Br J Ophthalmol 1998; 82: 1363-1365.
22. Roberto P et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension. The MAGIC Study. Hypertension 1997; 30: 1135-1143.
23. Biesenbach G, Zazgomik J. High prevalence of hypertensive retinopathy and coronary heart disease in hypertensive patients with persistent microalbuminuria under short intensive antihypertensive therapy. Clin Nephrol 1994; 41: 211-218.
24. Pose Reino A et al. Relation between left ventricular hypertrophy and retinal vascular changes in mild hypertension. Med Clin (Barc) 1997; 108: 281-285.
25. Shigematsu Y et al. Left ventricular geometry as an independent predictor for extracardiac target organ damage in essential hypertension. Am J Hypertens 1998; 11: 1171-1177.
26. Shigematsu Y et al. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997; 29: 723-727.
27. Uckaya G et al. Is leptin associated with hypertensive retinopathy? J Clin Endocrinol Metab 2000; 85: 683-687.
28. Bihorac A et al. Association between salt sensitivity and target organ damage in essential hypertension. Am J Hypertens 2000; 13: 864-872.
29. Heidbreder E, Huller U, Schafer B, Heidland A. Severe hypertensive retinopathy. Increased incidence in renoparenchymal hypertension. Am J Nephrol 1987; 7: 394-400.
30. Albers FJ. Clinical characteristics of atherosclerotic renovascular disease. Am J Kidney Dis 1994; 24: 636-641.
31. Akpunonu BE, Mulrow PJ, Hoffman EA. Secondary hypertension: evaluation and treatment. Dis Mon 1996; 42: 609-722.
32. Glodny B et al. Clinical differences between benign and malignant pheochromocytomas. Endocr J 2001; 48: 151-159.
33. Cuspidi C et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063-2070.
34. Ibrahim YW et al. Number of perifoveal vessels in aging, hypertension and atherosclerosis: the Rotterdam Study. Invest Ophthalmol Vis Sci 1998; 39: 1049-1053.
35. Kutschbach P et al. Retinal capillary density in patients with arterial hypertension: 2-year follow-up. Graefes Arch Clin Exp Ophthalmol 1998; 236: 410-414.
36. Chapman N et al. Acute effects of oxygen and carbon dioxide on retinal vascular network geometry in hypertensive and normotensive subjects. Clin Sci (Lond) 2000; 99: 483-488.
37. Stanton AV et al. Vascular network changes in the retina with age and hypertension. J Hypertens 1995; 13: 1724-1728.
38. Haefliger IO, Meyer P, Flammer J, Luescher TF. The vascular endothelium as a regulator of the ocular circulation: new concept in ophthalmology? Surv Ophthalmol 1994; 39: 123-132.
39. Hayreh SS, Servais GE, Virdi PS. Fundus lesions in malignant hypertension. V. Hypertensive optic neuropathy. Ophthalmology 1986; 93: 74-87.
40. Hayreh SS, Servais GE, Virdi PS. Fundus lesions in malignant hypertension. V. Hypertensive choroidopathy. Ophthalmology 1986; 93: 1383-1400.
41. Luescher TF. The endothelium and cardiovascular disease: a complex relationship. N Engl J Med 1994; 330: 1081-1083.
42. Liebreich R. Ophthalmoskopischer Befund bei Morbus Brightii. Albrecht von Graefes Arch Ophthalmol 1859; 5: 265-268.
43. Dodson PM et al. Hypertensive retinopathy: a review of existing classification systems and a suggestion for a simplified grading system. J Hum Hypertens 1996; 10: 93-98.
44. Hayreh SS. Classification of hypertensive fundus changes and their order of appearance. Ophthalmologica 1989; 198: 247-260.
45. Walsh JB. Hypertensive retinopathy: description, classification and prognosis. Ophthalmology 1982; 8: 1127-1131.
46. Hyman BN. The eye as a target organ: An updated classification of hypertensive retinopathy. J Clin Hypertens (Greenich) 2000; 2: 194-197.
47. Pache M, Kube T, Wotf S, Kutschbach P. Do angiographic data support a detailed classification of hypertensive fundus changes? J Hum Hypertens 2002; 16: 405-410.
48. Couper DJ et al. Reliability of retinal photography in the assessment of retinal microvascular characteristics: the atherosclerosis risk in communities study. Am J Ophthalmol 2002; 133: 78-88.
49. Patel V, Kohner EM. Eye in hypertension. In: Swales JD (ed). Text Book of Hypertension. Blackwell Scientific Publications: Oxford, 1994, pp 1015-1025.
50. Gass JDM. Stereoscopic Atlas of Macular Disease Diagnosis and Treatment, Vol 1. Mosby: St Louis, 1997, pp 467-476.
51. Bock KD. Regression of retinal vascular changes by anti-hypertensive therapy. Hypertension 1984; 6: 158-162.
52. Talks SJ et al. The acute and long-term ocular effects of accelerated hypertension: a clinical and electrophysiological study. Eye 1996; 10(Pt 3): 321-327.
53. Hamey BA, Hart JDC, Grey RHB. Atlas of Fluorescein Angiography. Wolfe: London 1994, pp 41-43.
54. Sharrett AR et al. Retinal arteriolar diameters and elevated blood pressure: the atherosclerosis risk in communities study. Am J Epidemiol 1999; 150: 263-270.
55. Keith NM, Wagener HP, Barker NW. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939; 197: 332-343.
56. McGregor E et al. Retinal changes in malignant hypertension. BMJ 1986; 282: 233-234.
57. Kishi S, Tso MOM, Hayreh SS. Fundus lesions in malignant hypertension. II. A pathologic study of experimental hypertensive optic neuropathy. Arch Ophthalmol 1985; 103: 1198-1206.
58. Isles CG. Hypertensive emergencies. In: Swales JD (ed). Text Book of Hypertension. Blackwell Scientific Publications: Oxford, 1994, pp 1233.
59. Lip GY, Beevers M, Dodson PM, Beevers DG. Severe hypertension with lone bilateral papilloedema: a variant of malignant hypertension. Blood Press 1995; 4: 339-342.
60. Hayreh SS, Jonas JB. Appearance of the optic disk and retinal nerve fiber layer in atherosclerosis and arterial hypertension: an experimental study in rhesus monkeys. Am J Ophthalmol 2000; 130: 91-96.
61. MacCumber MW, Flower RW, Langham ME. Ischemic hypertensive choroidopathy. Fluorescein angiography, indocyanine green videoangiography, and measurement of pulsatile blood flow. Arch Ophthalmol 1993; 111: 704-705.
62. Tso MO, Jampol LM. Pathophysiology of hypertensive retinopathy. Ophthalmology 1982; 89: 1132-1145.
63. Pohl ML. Siegrist's streaks in hypertensive choroidopathy. J Am Optom Assoc 1988; 59: 372-376.
64. Pierro L, Pece A, Camesasca F, Brancato R. Hypertensive choroidopathy: a case report. Int Ophthalmol 1991; 15: 9-14.
65. de Venecia G, Jampol LM. The eye in accelerated hypertension. II. Localized serous detachments of the retina in patients. Arch Ophthalmol 1984; 102: 68-73.
66. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularisation and vitreous haemorrhage in branch vein occlusion: a randomised clinical trial. Arch Ophthalmol 1986; 104: 34-41.
67. Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997; 115: 486-491.
68. Sperduto RD et al. Risk factors for hemiretinal vein occlusion: Comparison with risk factors for central and branch retinal vein occlusion: The eye disease case-control study. Ophthalmology 1998; 105: 765-771.
69. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: The Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98: 133-141 (discussion 141-143).
70. Recchia FM, Brown GC. Systemic disorders associated with retinal vascular occlusion. Curr Opin Ophthalmol 2000; 11: 462-467.
71. Barbon Garcia JJ et al. Macular vein occlusion in young people. Arch Soc Esp Oftalmol 2000; 75: 481-484 (in Spanish).
72. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131: 61-77.
73. Panton RW, Goldber MF, Farber MD. Retinal arterial macroaneurysms: Risk factors and natural history. Br J Ophthalmol 1990; 74: 595-600.
74. Rabb MF, Gagliano DA, Teske MP. Retinal arterial macroaneurysms. Surv Ophthalmol 1988; 33: 73-96.
75. Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with non-arteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 118: 766-780.
76. Repka MX et al. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol 1983; 96: 478-483.
77. Landau K et al. 24-hour blood pressure monitoring in patients with anterior ischemic optic neuropathy. Arch Ophthalmol 1996; 114: 570-575.
78. Hayreh SS, Podhajsky PA, Zimmerman B. Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica 1999; 213: 76-96.
79. Hayreh SS, Podhajsky PA, Zimmerman B. Non-arteritic anterior ischemic optic neuropathy - time of onset of visual loss. Am J Ophthalmol 1997; 124: 641-647.
80. HayreH SS, Podhajsky PA, Zimmerman B. Beta-blocker eye drops and nocturnal arterial hypotension. Am J Ophthalmol 1999; 128: 301-309.
81. Teuscher AU, Meienberg O. Ischaemic oculomotor nerve palsy. Clinical features and vascular risk factors in 23 patients. J Neurol 1985; 232: 144-149.
82. Tiffin PA, MacEwen CJ, Craig EA, Clayton G. Acquired palsy of the oculomotor, trochlear and abducens nerves. Eye 1996; 10: 377-384.
83. Berlit P. Isolated and combined pareses of cranial nerves III, IV and VI. A retrospective study of 412 patients. J Neurol Sci 1991; 103: 10-15.
84. Smilari P et al. Recurrent facial paralysis in a child with renovascular hypertension. Pediatr Med Chir 1995; 17: 461-463 (in Italian).
85. Richards BW, Jones FR Jr, Younge BR. Causes and prognosis in 4,278 cases of paralysis of the oculomotor, trochlear and abducens cranial nerves. Am J Ophthalmol 1992; 113: 489-496.
86. Grunwald JE et al. Diabetic glycaemic control and retinal blood flow. Diabetes 1990; 39: 602-607.
87. Stratton IM et al. UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia 2001; 44: 156-163.
88. JT Gillow, JM Gibson, PM Dodson. Hypertension and diabetic retinopathy - What's the story? Br J Ophthalmol 1999; 83: 1083-1087.
89. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000; 1: 18-20.